Concepts (99)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms | 7 | 2023 | 220 | 1.900 |
Why?
|
| Medical Oncology | 5 | 2023 | 43 | 1.390 |
Why?
|
| Mutation | 2 | 2019 | 330 | 1.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2016 | 240 | 0.840 |
Why?
|
| Patient Selection | 3 | 2022 | 170 | 0.840 |
Why?
|
| Spectrin | 2 | 2019 | 2 | 0.720 |
Why?
|
| Adolescent | 11 | 2023 | 1884 | 0.710 |
Why?
|
| Oncologists | 1 | 2021 | 2 | 0.690 |
Why?
|
| Leukemia, Large Granular Lymphocytic | 1 | 2020 | 1 | 0.650 |
Why?
|
| Cyclosporine | 1 | 2020 | 12 | 0.640 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 113 | 0.600 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2019 | 2 | 0.590 |
Why?
|
| MDS1 and EVI1 Complex Locus Protein | 1 | 2019 | 3 | 0.590 |
Why?
|
| Influenza B virus | 1 | 2019 | 1 | 0.580 |
Why?
|
| Atypical Hemolytic Uremic Syndrome | 1 | 2019 | 1 | 0.580 |
Why?
|
| Membrane Cofactor Protein | 1 | 2019 | 2 | 0.580 |
Why?
|
| Medically Underserved Area | 1 | 2019 | 13 | 0.580 |
Why?
|
| Plasma Exchange | 1 | 2019 | 11 | 0.580 |
Why?
|
| Spherocytosis, Hereditary | 1 | 2018 | 1 | 0.570 |
Why?
|
| Genes, Recessive | 1 | 2018 | 3 | 0.570 |
Why?
|
| MicroRNAs | 1 | 2019 | 38 | 0.570 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2019 | 51 | 0.570 |
Why?
|
| Influenza, Human | 1 | 2019 | 40 | 0.570 |
Why?
|
| Epigenesis, Genetic | 1 | 2019 | 60 | 0.560 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 83 | 0.550 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 72 | 0.550 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 96 | 0.550 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2019 | 95 | 0.540 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 277 | 0.520 |
Why?
|
| Child | 7 | 2023 | 1161 | 0.510 |
Why?
|
| Young Adult | 8 | 2023 | 1659 | 0.500 |
Why?
|
| Histiocytic Sarcoma | 1 | 2016 | 2 | 0.500 |
Why?
|
| Orbital Neoplasms | 1 | 2016 | 6 | 0.500 |
Why?
|
| Humans | 19 | 2023 | 23238 | 0.470 |
Why?
|
| Heavy Chain Disease | 1 | 2015 | 1 | 0.450 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2015 | 5 | 0.440 |
Why?
|
| Prognosis | 4 | 2020 | 730 | 0.430 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2014 | 8 | 0.410 |
Why?
|
| Membrane Proteins | 1 | 2014 | 140 | 0.390 |
Why?
|
| Osteosarcoma | 1 | 2013 | 36 | 0.390 |
Why?
|
| Clinical Trials as Topic | 3 | 2022 | 192 | 0.360 |
Why?
|
| Bone Neoplasms | 1 | 2013 | 118 | 0.360 |
Why?
|
| Male | 9 | 2020 | 12676 | 0.320 |
Why?
|
| Quality of Life | 3 | 2023 | 565 | 0.220 |
Why?
|
| Communication | 2 | 2022 | 96 | 0.210 |
Why?
|
| Fertility Preservation | 1 | 2022 | 2 | 0.190 |
Why?
|
| Quality Improvement | 1 | 2022 | 128 | 0.170 |
Why?
|
| Cell Line, Tumor | 2 | 2019 | 246 | 0.170 |
Why?
|
| Female | 6 | 2020 | 13161 | 0.170 |
Why?
|
| Child Health | 1 | 2020 | 3 | 0.160 |
Why?
|
| Infant | 2 | 2018 | 485 | 0.160 |
Why?
|
| Administration, Oral | 1 | 2020 | 96 | 0.160 |
Why?
|
| Anemia, Hemolytic, Congenital | 1 | 2019 | 1 | 0.150 |
Why?
|
| RNA Splice Sites | 1 | 2019 | 2 | 0.150 |
Why?
|
| Erythrocyte Membrane | 1 | 2019 | 2 | 0.150 |
Why?
|
| RNA Splicing | 1 | 2019 | 6 | 0.150 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 779 | 0.150 |
Why?
|
| Mutation, Missense | 1 | 2019 | 26 | 0.150 |
Why?
|
| Oligoribonucleotides | 1 | 2019 | 1 | 0.150 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 23 | 0.150 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2019 | 17 | 0.150 |
Why?
|
| Survival Analysis | 1 | 2019 | 226 | 0.140 |
Why?
|
| Child, Preschool | 2 | 2018 | 571 | 0.140 |
Why?
|
| Cell Proliferation | 1 | 2019 | 166 | 0.140 |
Why?
|
| Apoptosis | 1 | 2019 | 197 | 0.140 |
Why?
|
| Mice | 2 | 2019 | 1252 | 0.130 |
Why?
|
| DNA Methylation | 1 | 2019 | 129 | 0.130 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2017 | 31 | 0.130 |
Why?
|
| Signal Transduction | 1 | 2019 | 388 | 0.130 |
Why?
|
| Adult | 4 | 2022 | 6974 | 0.130 |
Why?
|
| Age Factors | 1 | 2019 | 651 | 0.120 |
Why?
|
| beta Catenin | 1 | 2017 | 58 | 0.120 |
Why?
|
| Nitrogen Mustard Compounds | 1 | 2015 | 1 | 0.110 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2015 | 5 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2015 | 26 | 0.110 |
Why?
|
| Rituximab | 1 | 2015 | 38 | 0.110 |
Why?
|
| Animals | 2 | 2019 | 3306 | 0.110 |
Why?
|
| Metastasectomy | 1 | 2013 | 7 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 878 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 202 | 0.090 |
Why?
|
| Retrospective Studies | 1 | 2019 | 2994 | 0.080 |
Why?
|
| Treatment Outcome | 1 | 2016 | 2946 | 0.070 |
Why?
|
| Lung Neoplasms | 1 | 2013 | 540 | 0.070 |
Why?
|
| Risk Factors | 1 | 2013 | 2022 | 0.070 |
Why?
|
| Cancer Care Facilities | 1 | 2023 | 6 | 0.050 |
Why?
|
| Survivors | 1 | 2022 | 69 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 122 | 0.050 |
Why?
|
| Technology | 1 | 2021 | 5 | 0.040 |
Why?
|
| Pandemics | 1 | 2021 | 207 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2018 | 20 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2017 | 2 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 2017 | 16 | 0.030 |
Why?
|
| Heterografts | 1 | 2017 | 16 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2017 | 100 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2017 | 132 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 247 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2017 | 175 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2018 | 540 | 0.030 |
Why?
|
| United States | 1 | 2018 | 1805 | 0.020 |
Why?
|